Form 13-F position report

BIOMARIN PHARMACEUTICAL INC

Reported by STEPHENS INC AR

BMRN 0.599 08/01/24 CUSIP 09061GAH4 Manager CIK 0000757657

Reported 0 shares, down 139,000 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q2 2024
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 18 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 45000
2022-03-31 65000
2022-06-30 59000
2022-09-30 59000
2022-12-31 63678
2023-03-31 61559
2023-06-30 58936
2023-09-30 58200
2023-12-31 90675
2024-03-31 136484
2024-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

11 quarters
Quarterly reported position history for BIOMARIN PHARMACEUTICAL INC held by STEPHENS INC AR.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2024 Reduced 0 -139,000 (-100.0%) 0 $0 2024-08-06
Q1 2024 Added 139,000 +47,000 (51.1%) < 0.01% $136,484 2024-05-15
Q4 2023 Added 92,000 +32,000 (53.3%) < 0.01% $90,675 2024-02-13
Q3 2023 Unchanged 60,000 0 (0.0%) < 0.01% $58,200 2023-11-14
Q2 2023 Unchanged 60,000 0 (0.0%) < 0.01% $58,936 2023-08-14
Q1 2023 Unchanged 60,000 0 (0.0%) < 0.01% $61,559 2023-05-15
Q4 2022 Unchanged 60,000 0 (0.0%) < 0.01% $63,678 2023-01-25
Q3 2022 Unchanged 60,000 0 (0.0%) < 0.01% $59,000 2022-11-02
Q2 2022 Reduced 60,000 -5,000 (-7.7%) < 0.01% $59,000 2022-08-03
Q1 2022 Added 65,000 +22,000 (51.2%) < 0.01% $65,000 2022-05-04
Q4 2021 Unchanged 43,000 0 (0.0%) < 0.01% $45,000 2022-03-07
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

68 managers reported BIOMARIN PHARMACEUTICAL INC for Q2 2024.

Managers reporting BIOMARIN PHARMACEUTICAL INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
OSTERWEIS CAPITAL MANAGEMENT INC New 82,159,000 +82,159,000 4.22% $81,690,584 1 qtr
Sculptor Capital LP New 48,584,000 +48,584,000 0.91% $48,334,278 3 qtrs
MILLENNIUM MANAGEMENT LLC Unchanged 0 0 0.02% $43,774,133 3 qtrs
LAZARD ASSET MANAGEMENT LLC Added 39,712,000 +612,000 0.05% $39,485,000 7 qtrs
Voya Investment Management LLC Reduced 38,250,000 -2,290,000 0.04% $38,031,924 8 qtrs
GLAZER CAPITAL LLC Unchanged 0 0 2.31% $29,748,000 1 qtr
Citigroup Inc Added 26,484,000 +567,000 0.02% $26,266,831 7 qtrs
AVIVA PLC Reduced 25,000,000 -500,000 0.07% $24,755,475 6 qtrs
TENOR CAPITAL MANAGEMENT Co L P Added 23,693,000 +2,031,000 0.37% $23,648,082 3 qtrs
PIPER SANDLER & CO New 21,581,000 +21,581,000 16.66% $21,311,238 1 qtr
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 06, 2024
Filing type
13F-HR
Position type
NOTE 0.599% 8/0

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.